Clinical Trial

A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpse of this study is to evaluate the safety and tolerability of KSD-101 in the treatment of relapsed or refractory EBV-associated hematological malignancies,to preliminarily explore the clinical efficacy ,evaluate the immune response to KSD-101 for the treatment in Patients with EBV-associated hematological diseases and the improvement in subjects' quality of life (QOL) after KSD-101 treatment.
Trial Details
NCT Number NCT07532746
Lead Sponsor Kousai Bio Co., Ltd.
Conditions Relapsed or Refractory EBV-associated Hematological Malignancies
Enrollment 55 participants
Start Date 2026-05-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-16